Canada· CA-DIN-02539888

LIVMARLI

A maralixibat chloride product containing maralixibat (maralixibat chloride), registered in Canada by MIRUM PHARMACEUTICALS, INC.. The same ATC class is registered in 11 of our 19 countries.

ATC A05AX04

Checked against Health Canada Drug Product Database (Canada) on

Informational only — not a medical device.

SOURCE REGISTER · CAHealth Canada Drug Product Database (Ca…normalisedLIVMARLIATCA05AX04REGISTER NO.CA-DIN-02539888PACKS LISTED0CHECKEDOctober 1, 2026

Where it is registered

Maralixibat chloride is registered in 11 of 19 countries.

Countries holding a registration under ATC A05AX04 (maralixibat chloride), each read from that country’s own register.

  • This record: Canada, from Health Canada Drug Product Database (Canada)
  • 6 of them publish a price we can compare per daily dose

Maralixibat chloride · ATC A05AX04

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Health Canada Drug Product Database (Canada)
Active substance
MARALIXIBAT (MARALIXIBAT CHLORIDE)
Manufacturer
MIRUM PHARMACEUTICALS, INC.
Country
Canada (CA)
ATC code
A05AX04
ATC class
Maralixibat chloride
Defined daily dose
28.5 mg, O
Reimbursed
Not published by this register
Source register
Health Canada Drug Product Database (Canada)
Last checked
October 1, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Maralixibat chloride in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All maralixibat chloride products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Livmarli
  • Liechtenstein · Livmarli
  • Norway · Livmarli

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bea085ed-b3ee-4585-9522-214ac752d52d
GET /v1/drugs/bea085ed-b3ee-4585-9522-214ac752d52d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "din": "02539888",
  "form": "SOLUTION",
  "class": "Human",
  "routes": [
    "ORAL"
  ],
  "source": "health_canada_dpd",
  "status": "MARKETED",
  "atc_raw": "A05AX04",
  "schedule": [
    "Prescription"
  ],
  "drug_code": "102861",
  "strengths": [
    "9.5 MG"
  ],
  "ahfs_class": null,
  "substances": [
    "MARALIXIBAT (MARALIXIBAT CHLORIDE)"
  ],
  "product_categorization": null
}

See everything about maralixibat chloride.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.